Drug Approval | May 19, 2026
Astrazeneca’s Baxfendy wins US approval as first-in-class hypertension drug
Baxfendy works in a fundamentally different way from current therapies
Baxfendy works in a fundamentally different way from current therapies
The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies
The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments
India’s institutions now need to upgrade TTOs as strategic innovation units rather than administrative support cells
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
The ISG assessment highlights Indegene’s deep domain expertise, proprietary technology stack, and expanding use of AI and GenAI to drive more integrated, data-led commercial execution across the life sciences value chain
Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
Both join the leading CRDMO’s executive committee to drive global people strategy and commercial expansion
On his visit to NIPER Mohali, union health minister vreviews biopharma research initiatives and calls for stronger industry collaboration and commercialization focus
The company doses first patient in US study of Deraphan, as Dolby Ventures joins €53M Series B to support neuropsychiatric innovation
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
